DOCSLIB.ORG

Book of Abstracts 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Book of Abstracts 2016 BOOK OF ABSTRACTS BOOK OF ABSTRACTS 2016 Organised by: On behalf of: EFMC-ISMC 2016 tel. office: +32 10 45 47 77 All information in this Manchester, UK, 2016 SYMPOSIUM SECRETARIAT tel. onsite in Manchester: +32 495 240864 programme book is accurate LD Organisation s.p.r.l. mail: [email protected] at the time of printing August 28-September 1 Scientific Conference Producers website: www.efmc-ismc.org Rue Michel de Ghelderode 33/2 www.efmc-ismc.org 1348 Louvain-la-Neuve, Belgium TABLE OF CONTENT Plenary Lectures 3 Award & Prize Lectures 11 Invited Lectures & Oral Communications 19 Posters 121 Drug Discovery Approaches Toward Targeting Ras 121 New Antibacterials. An Update 123 Peptides: Pushing Permeability and Bioavailability Beyond the Rule of 5 139 Molecular Tissue Targeting 143 First Time Disclosures 147 Making Small Molecule Synthesis Simpler, General, and Automatic 153 Hot Topics in Cardiovascular Diseases Research 163 Neglected Diseases 171 Synthesis Driven Innovation 195 Modulation of Protein-Protein Interactions - Novel Opportunities for Drug Discovery 213 Current Advances and Future Opportunities for the Treatment of Neurodegenerative Disorders 225 Big Data in Medicinal Chemistry 243 New Horizons in GPCR-targeted Medicinal Chemistry 249 Novel Approaches to the Treatment of Cancer 263 Emerging Topics 295 Innovation in Kinase Drug Discovery 305 The Importance of Solute Carrier Transporters in Drug Discovery 319 Covalent Drugs Revisited 323 Novel Molecular Probes for in Vivo Chemistry 327 Recent Advances on Approaches to Treat Pain 331 High Throughput Screening Strategies to Obtain High Quality Leads 335 Late Breaking News 343 Showcase Brazil 347 Other 349 Index of Abstracts 377 Index of Authors 407 1 NOTES 2 PLENARY LECTURES 3 PL001 SCIENCE, ART AND DRUG DISCOVERY, A PERSONAL PERSPECTIVE Simon Campbell CBE FRS Former SVP for WW Discovery at Pfizer [email protected] At the start of our research programme that lead to amlodipine, a once-daily calcium antagonist for the treatment of angina and hypertension, there were over 90 published patents around the parent dihydropyridine ring system which posed a significant challenge for innovative drug design. Moreover, all agents of the class suffered poor pharmacokinetics, and there was little information on how these might be improved. However, rational medicinal chemistry led to a novel series of dihydropyridines with potent calcium antagonist activity which displayed high, and uniform bioavailability, together with long plasma half-lives. After extensive pharmacological profiling, UK 48,340 (amlodipine) was selected for clinical development and subsequently received worldwide approval as Norvascä for the treatment of hypertension and angina. Norvascä became the world’s leading antihypertensive agent and the fourth best selling drug, with some billions of patient days of therapy achieved since launch Sildenafil, the first oral treatment for male erectile dysfunction, was the result of a cardiovascular research programme to block the action of PDE 5 and increase tissue levels of cGMP, even though the endogenous ligand that stimulated guanylate cyclase was unknown at the time. Starting from zaprinast, a weak and non-selective PDE 5 inhibitor, computer modelling guided rational medicinal chemistry to achieve significant increases in potency and selectivity within a novel series of pyrazolopyrimidones. Optimisation of SARs and pharmacokinetics led to UK 92,480 (sildenafil) that was essentially devoid of cardiovascular activity in clinical trials. However, the emerging role of nitric oxide and cGMP in controlling blood flow in the penis suggested that sildenafil would have a beneficial effect on erectile dysfunction. This hypothesis was confirmed by extensive clinical trials in nearly 5,000 patients and sildenafil was approved as Viagraä for the treatment of male erectile dysfunction. Viagraä became one of the most widely prescribed medicines, and has been used by 100s of millions of patients throughout the World. These research programmes will be discussed from a personal perspective that will highlight the importance of multidisciplinary project teams, challenges that arose during discovery and development, and factors that influenced key decisions. 4 PL002 THE EUROPEAN RESEARCH COUNCIL (ERC) AND ITS SUPPORT FOR MEDICINAL CHEMISTRY Klaus Bock University of Copenhagen Set up in 2007 by the European Union, the fundamental activity of the European Research Council (ERC) is to provide attractive, long-term funding to support excellent investigators and their research teams to pursue ground-breaking, high-gain/ high-risk research. Supporting best researchers in any field of research on the sole criterion of excellence is expected to have a direct impact through advances at the frontier of knowledge, opening the way to creating new scientific and technological results, which ultimately can lead to innovation. The ERC uses a typical panel-based peer-review system, in which panels of high-level scientists and/or scholars make recommendations for funding. The ERC panel structure consists of 25 panels across three domains: Social sciences and Humanities (SH), Life sciences (LS), Physical and Engineering Sciences (PE). At ERC chemical research is funded mainly in two big panels: PE4 “Physical and Analytical Chemical Sciences” and PE5 “Synthetic Chemistry and Materials”. Around 580 Starting, Consolidator and Advanced grants were awarded between 2007 and 2015 in these two panels with a total value of 1 billion euro (or almost 10% of the entire ERC budget awarded to the three main types of grants in this period). About 1 in 6 grants in panels PE4 and PE5 are working on medicinal chemistry or perform research with impact in medicine and on medical applications (including drugs). The areas where ERC grantees are most active are: - the creation of new molecular entities and subsequent exploitation of their properties for drug design and synthesis. The problems and difficulties associated with chemical syntheses (e.g. more rapid and robust techniques in organic synthesis) are addressed in many of these grants. A few projects are in the area of bioinorganic chemistry and explore new therapeutic applications of metal complexes. Other projects tend to focus on mechanistic studies of biochemical processes and reactions, on proteomics and on new approaches in drug design and delivery. Projects dealing with drug design cover a broad spectrum of research questions, ranging from development and analysis of new drugs and their impact on specific diseases (cancer, Alzheimer's disease, HIV, etc.) to the development of improved methods for drug analysis (more selective and efficient screening methods, enhancing the existing libraries of spectra of compounds, etc.); - research for improved diagnosis, early diagnosis and prognosis for preventive and personalized medicine; - design and preparation of new materials that interact with components of living systems in view of therapeutic or diagnostic applications. Materials targeted by these projects are, for example, hydrogels with applications in tissue engineering and repair, optical metamaterials, supramolecular biomaterials etc. Nanoscale engineering is a promising road for the development of novel materials with tailor-made properties, achieved by precise control of the materials structure and composition; - development of advanced imaging techniques (e.g. magnetic resonance, surgical imaging) or spectroscopic methods used in medicine. Projects doing research in medicinal chemistry are found in other ERC panels as well, especially in some of the LS panels and, to a lesser degree, in the engineering panels (PE7 “Systems and communication engineering” and PE8 “Products and process engineering”). My presentation will offer more details on the scope and objectives of ERC projects in medicinal chemistry as well as information about their results. 5 PL003 LATE-STAGE FLUORINATION Tobias Ritter (1,2,3) 1) Max-Planck-Institut fuer Kohlenforschung Kaiser-Wilhelm-Platz 1, 45470 Muelheim Germany 2) Harvard University Department of Chemistry and Chemical Biology 12 Oxford Street, Cambridge, MA 02138 USA 3) Massachusetts General Hospital Department of Radiology 55 Fruit Street, Boston, MA 02129 USA The unnatural isotope fluorine–18 (18F) is used as a positron emitter in molecular imaging. Currently, many potentially useful 18F-labeled probe molecules are inaccessible for imaging, because no fluorination chemistry is available to make them. Syntheses must be rapid on account of the 110-minute half-life of 18F and benefit from using [18F]fluoride due to practical access and suitable isotope enrichment. But [18F]fluoride chemistry has been limited in reaction and substrate scope. I will describe the development of novel, modern fluorination reactions and evaluate them based on their utility for F-19 and F-18 chemistry. Late-stage fluorination enables the synthesis of new drug candidates and conventionally unavailable positron emission tomography (PET) tracers for anticipated applications in pharmaceutical development as well as pre-clinical and clinical PET imaging. References 1) T. Furuya, A. S. Kamlet, T. Ritter “Catalysis for Fluorination and Trifluoromethylation” Nature, 2011, 473, 470. 2) E. Lee, A. S. Kamlet, D. C. Powers, C. N. Neumann, G. B. Boursalian, T. Furuya, D. C. Choi, J. M. Hooker, T. Ritter “A fluoride-derived electrophilic late-stage fluorination reagent for PET imaging” Science 2011, 334, 639. 3) C. N. Neumann, J. M. Hooker, T. Ritter
Load more

Recommended publications
  • Phd Thesis ZHANG Kaixi.Pdf
    This document is downloaded from DR‑NTU (https://dr.ntu.edu.sg) Nanyang Technological University, Singapore. Glycosylated cationic block co‑beta‑peptide as antimicrobial and anti‑biofilm agents against Gram‑positive bacteria Zhang, Kaixi 2019 Zhang, K. (2019). Glycosylated cationic block co‑beta‑peptide as antimicrobial and anti‑biofilm agents against Gram‑positive bacteria. Doctoral thesis, Nanyang Technological University, Singapore. https://hdl.handle.net/10356/137037 https://doi.org/10.32657/10356/137037 This work is licensed under a Creative Commons Attribution‑NonCommercial 4.0 International License (CC BY‑NC 4.0). Downloaded on 11 Oct 2021 00:27:16 SGT GLYCOSYLATED CATIONIC BLOCK CO-BETA-PEPTIDE AS ANTIMICROBIAL AND ANTI-BIOFILM AGENTS AGAINST GRAM- POSITIVE BACTERIA ZHANG KAIXI Interdisciplinary Graduate School HealthTech NTU 2019 Sample of first page in hard bound thesis I Glycosylated cationic block co-beta-peptide as antimicrobial and anti-biofilm agents against Gram-positive bacteria ZHANG KAIXI Interdisciplinary Graduate School HealthTech NTU A thesis submitted to the Nanyang Technological University in partial fulfillment of the requirement for the degree of Doctor of Philosophy 2019 i Statement of Originality I hereby certify that the work embodied in this thesis is the result of original research, is free of plagiarised materials, and has not been submitted for a higher degree to any other University or Institution. 18 Dec 2019 Date ZHANG KAIXI ii Supervisor Declaration Statement I have reviewed the content and presentation style of this thesis and declare it is free of plagiarism and of sufficient grammatical clarity to be examined. To the best of my knowledge, the research and writing are those of the candidate except as acknowledged in the Author Attribution Statement.
    [Show full text]
  • Uk Energy Storage Research Capability Document Capturing the Energy Storage Academic Research Landscape
    UK ENERGY STORAGE RESEARCH CAPABILITY DOCUMENT CAPTURING THE ENERGY STORAGE ACADEMIC RESEARCH LANDSCAPE June 2016 CONTENTS CONTENTS PAGE NUMBER INTRODUCTION 5 BIOGRAPHIES Dr Ainara Aguadero, Imperial College 10 Dr Maria Alfredsson, Kent 11 Dr Daniel Auger, Cranfield 12 Dr Audrius Bagdanavicius, Leicester 13 Prof Philip Bartlett, Southampton 14 Dr Léonard Berlouis, Strathclyde 15 Dr Rohit Bhagat, Warwick 16 Dr Nuno Bimbo, Lancaster 17 Dr Frédéric Blanc, Liverpool 18 Prof Nigel Brandon, Imperial College 19 Dr Dan Brett, UCL 20 Prof Peter Bruce, Oxford 21 Dr Jonathan Busby, British Geological Survey 22 Dr Qiong Cai, Surrey 23 Prof George Chen, Nottigham 24 Prof Rui Chen, Loughborough 25 Prof Simon Clarke, Oxford 26 Dr Liana Cipcigan, Cardiff 27 Dr Paul Alexander Connor, St Andrews 28 Dr Serena Corr, Glasgow 29 Prof Bob Critoph, Warwick 30 Prof Andrew Cruden, Southampton 31 Dr Eddie Cussen, Strathclyde 32 Prof Jawwad Darr, UCL 33 Dr Prodip Das, Newcastle 34 Dr Chris Dent, Durham 35 Prof Yulong Ding, Birmingham 36 Prof Robert Dryfe, Manchester 37 Prof Stephen Duncan, Oxford 38 Dr Siân Dutton, Cambridge 39 Dr David Evans, British Geological Survey 40 Prof Stephen Fletcher, Loughborough 41 3 UK Energy Superstore Research Capability Document CONTENTS CONTENTS Dr Rupert Gammon, De Montfort University 42 Dr Nuria Garcia-Araez, Southampton 43 Prof Seamus Garvey, Nottingham 44 Dr Monica Giulietti, Cambridge 45 Prof Bartek A. Glowacki, Cambridge 46 Prof David Grant, Nottingham 47 Prof Patrick Grant, Oxford 48 Prof Richard Green, Imperial College 49
    [Show full text]
  • Abstract Book – Oral Sessions
    Sunday, June 21, 2015 12:00 p.m. - 1:15 p.m. Latin American Psychopharmacology Update: INNOVATIVE TREATMENTS IN PSYCHIATRY INNOVATIVE TREATMENTS IN PSYCHIATRY Flavio Kapczinski, The University of Texas Health Science Center at Houston Overall Abstract In this panel, we will propose innovative treatments in psychiatry and recent literature findings will be summarized. The effective pharmacological treatment of psychiatric diseases and development of new therapeutic entities has been a long-standing challenge. Despite the complexity and heterogeneity of psychiatric disorders, basic and clinical research studies and technological advancements in genomics, biomarkers, and imaging have begun to elucidate the pathophysiology of etiological complexity of psychiatric diseases and to identify efficacious new agents (Tcheremissine et al. 2014). Many psychiatric illnesses are associated with neuronal atrophy, characterized by loss of synaptic connections, increase of inflammatory markers like TNF-α and DAMPS (damage-associate molecular patterns,- cell free (ccf) DNA, heat shock proteins HSP70, HSP90, and HSP60, and cytochrome C), decrease of neurotrophic factors, increase of oxidative stress, mitochondrial dysfunction and apoptosis (Fries et al., 2012; Pfaffenseller et al., 2014). Also, neurocognitive impairment and poor psychosocial functioning has been related to a psychiatric disease. Therefore, trying to discover new therapeutic targets that act in these pathways can help to develop new treatment or improve the treatment of these serious diseases.
    [Show full text]
  • Inhibiting IDO Pathways to Treat Cancer: Lessons from the ECHO-301 Trial and Beyond
    Seminars in Immunopathology (2019) 41:41–48 https://doi.org/10.1007/s00281-018-0702-0 REVIEW Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond Alexander J. Muller1 & Mark G. Manfredi2 & Yousef Zakharia3 & George C. Prendergast1 Received: 8 August 2018 /Accepted: 13 August 2018 /Published online: 10 September 2018 # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract With immunotherapy enjoying a rapid resurgence based on the achievement of durable remissions in some patients with agents that derepress immune function, commonly referred to as Bcheckpoint inhibitors,^ enormous attention developed around the IDO1 enzyme as a metabolic mediator of immune escape in cancer. In particular, outcomes of multiple phase 1/2 trials encouraged the idea that small molecule inhibitors of IDO1 may improve patient responses to anti-PD1 immune checkpoint therapy. However, recent results from ECHO-301, the first large phase 3 trial to evaluate an IDO1-selective enzyme inhibitor (epacadostat) in combinationwithananti-PD1antibody(pembrolizumab)inadvanced melanoma, showed no indication that epacadostat provided an increased benefit. Here we discuss several caveats associated with this failed trial. First is the uncertainty as to whether the target was adequately inhibited. In particular, there remains a lack of direct evidence regarding the degree of IDO1 inhibition within the tumor, and previous trial data suggest that sufficient drug exposure may not have been achieved at the dose tested in ECHO-301. Second, while there is a mechanistic rationale for the combination tested, the preclinical data were not particularly compelling. More efficacious combinations have been demonstrated with DNA damaging modalities which may therefore be a more attractive alternative.
    [Show full text]
  • Neuroendocrine and Sympathetic Responses to an Orexin Receptor Antagonist, SB-649868, and Alprazolam Following Insulin-Induced Hypoglycemia in Humans
    Psychopharmacology (2014) 231:3817–3828 DOI 10.1007/s00213-014-3520-7 ORIGINAL INVESTIGATION Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans Ameera X. Patel & Sam R. Miller & Pradeep J. Nathan & Ponmani Kanakaraj & Antonella Napolitano & Philip Lawrence & Annelize Koch & Edward T. Bullmore Received: 8 October 2013 /Accepted: 24 February 2014 /Published online: 26 April 2014 # The Author(s) 2014. This article is published with open access at Springerlink.com Abstract it has previously been validated using the insulin tolerance test Rationale The orexin-hypocretin system is important for (ITT) model in humans. translating peripheral metabolic signals and central neuronal Results Of the primary endpoints, ITT induced defined in- inputs to a diverse range of behaviors, from feeding, motiva- creases in pulse rate, plasma cortisol, and adrenocorticotropic tion and arousal, to sleep and wakefulness. Orexin signaling is hormone in the placebo condition, but these responses were thus an exciting potential therapeutic target for disorders of not significantly impacted by alprazolam or SB-649868 pre- sleep, feeding, addiction, and stress. treatment. Of the secondary endpoints, ITT induced a defined Objectives/methods Here, we investigated the low dose phar- increase in plasma concentrations of adrenaline, noradrena- macology of orexin receptor antagonist, SB-649868, on neu- line, growth hormone (GH), and prolactin in the placebo roendocrine, sympathetic nervous system, and behavioral re- condition. Alprazolam pre-treatment significantly reduced sponses to insulin-induced hypoglycemic stress, in 24 healthy the GH response to ITT (p<0.003), the peak electromyogra- male subjects (aged 18–45 years; BMI 19.0–25.9 kg/m2), phy (p<0.0001) and galvanic skin response (GSR, p=0.04)to using a randomized, double-blind, placebo-controlled, acoustic startle, the resting GSR (p=0.01), and increased within-subject crossover design.
    [Show full text]
  • ORGANIC CHEMISTRY Alkynes
    University of Michigan new functional groups. (3) Developing novel routes for functionalizing readily available organic building blocks DEPARTMENT OF CHEMISTRY such as alkenes and alkynes. (4) Exploring the reduc- tive coupling of aldehydes and alkynes or enones and ORGANIC CHEMISTRY alkynes. Recent studies have demonstrated strategies involving redox isomerization to avoid the use of reduc- Graduate Program ing agents in processes of this type. (5) The discovery of new glycosylation methods and their application in collaborative projects involving enzymatic C-H oxida- tion reactions. Traditional Synthetic Novel C–H Bond Approach Functionalization Approach Fluorinated amino acids can be used to make super-stable “Tef- O O N O NH N lon” proteins; here the interior of a small protein is packed with the Michigan offers a diverse selection of research oppor- 2 Br 1. Br cat. PdII fluorous amino acid hexafluoroleucine (Marsh). O N tunities in Organic Chemistry with particular strengths Y Y Y N 2. NH3/MeOH Oxidant–X in Organometallic Chemistry, Organic Synthesis, Bioor- X X H 3. CH3I ganic Chemistry, and Organic Materials. Our innovative treatment of autoimmune diseases and cancer. (3) Anti-anxiety research rotation program allows students to explore Anti-convulsant Developing and applying chemical tools to study a range of exciting possibilities before choosing an Palladium-catalyzed C-H functionalization of an arene (Sanford). the role of oxidants as signaling molecules and the advisor. Specific research projects in each area are biological basis of aging. (4) Elucidating catalytic highlighted below. mechanisms and essential active site features of me- talloenzymes and ribozymes, including protein farnes- Organic Synthesis yltransferase, UDP-3-O-acyl-GlcNAC deacetylase, his- R3 H tone deacetylase and ribonuclease P.
    [Show full text]
  • Orexin Receptor Antagonists As Therapeutic Agents for Insomnia
    REVIEW ARTICLE published: 25 December 2013 doi: 10.3389/fphar.2013.00163 Orexin receptor antagonists as therapeutic agents for insomnia Ana C. Equihua 1, Alberto K. De La Herrán-Arita 2 and Rene Drucker-Colin 1* 1 Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, México 2 Center for Sleep Sciences and Medicine, Stanford University, Palo Alto, CA, USA Edited by: Insomnia is a common clinical condition characterized by difficulty initiating or maintaining Christopher J. Winrow, Merck, USA sleep, or non-restorative sleep with impairment of daytime functioning. Currently, Reviewed by: treatment for insomnia involves a combination of cognitive behavioral therapy (CBTi) Matthew R. Ebben, Weill Medical and pharmacological therapy. Among pharmacological interventions, the most evidence College of Cornell University, USA Gabriella Gobbi, McGill University, exists for benzodiazepine (BZD) receptor agonist drugs (GABAA receptor), although Canada concerns persist regarding their safety and their limited efficacy. The use of these Matt Carter, University of hypnotic medications must be carefully monitored for adverse effects. Orexin (hypocretin) Washington, USA neuropeptides have been shown to regulate transitions between wakefulness and Michihiro Mieda, Kanazawa University, Japan sleep by promoting cholinergic/monoaminergic neural pathways. This has led to the *Correspondence: development of a new class of pharmacological agents that antagonize the physiological Rene Drucker-Colin, Departamento effects of orexin. The development of these agents may lead to novel therapies for de Neurociencias, Instituto de insomnia without the side effect profile of hypnotics (e.g., impaired cognition, disturbed Fisiología Celular, Universidad arousal, and motor balance difficulties). However, antagonizing a system that regulates Nacional Autónoma de México, Circuito exterior S/N, Apdo.
    [Show full text]
  • TRP Channel Transient Receptor Potential Channels
    TRP Channel Transient receptor potential channels TRP Channel (Transient receptor potential channel) is a group of ion channels located mostly on the plasma membrane of numerous human and animal cell types. There are about 28 TRP channels that share some structural similarity to each other. These are grouped into two broad groups: Group 1 includes TRPC ("C" for canonical), TRPV ("V" for vanilloid), TRPM ("M" for melastatin), TRPN, and TRPA. In group 2, there are TRPP ("P" for polycystic) and TRPML ("ML" for mucolipin). Many of these channels mediate a variety of sensations like the sensations of pain, hotness, warmth or coldness, different kinds of tastes, pressure, and vision. TRP channels are relatively non-selectively permeable to cations, including sodium, calcium and magnesium. TRP channels are initially discovered in trp-mutant strain of the fruit fly Drosophila. Later, TRP channels are found in vertebrates where they are ubiquitously expressed in many cell types and tissues. TRP channels are important for human health as mutations in at least four TRP channels underlie disease. www.MedChemExpress.com 1 TRP Channel Inhibitors, Antagonists, Agonists, Activators & Modulators (-)-Menthol (E)-Cardamonin Cat. No.: HY-75161 ((E)-Cardamomin; (E)-Alpinetin chalcone) Cat. No.: HY-N1378 (-)-Menthol is a key component of peppermint oil (E)-Cardamonin ((E)-Cardamomin) is a novel that binds and activates transient receptor antagonist of hTRPA1 cation channel with an IC50 potential melastatin 8 (TRPM8), a of 454 nM. Ca2+-permeable nonselective cation channel, to 2+ increase [Ca ]i. Antitumor activity. Purity: >98.0% Purity: 99.81% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg, 1 g Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg (Z)-Capsaicin 1,4-Cineole (Zucapsaicin; Civamide; cis-Capsaicin) Cat.
    [Show full text]
  • FEPS 2019 – BOLOGNA (ITALY) Abstracts of the Joint Meeting
    www.actaphysiol.org September 2019 • Volume 227 • Supplement 718 OFFICIAL JOURNAL OF THE FEDERATION OF EUROPEAN PHYSIOLOGICAL SOCIETIES FEPS 2019 – BOLOGNA (ITALY) Joint Meeting of the Federation of European Physiological Societies (FEPS) and the Italian Physiological Society (SIF) Bologna (Italy), September 10th – 13th 2019 Abstracts of the Joint Meeting A Joint International Meeting celebrating the 70th Anniversary of the Italian Physiological Society PUBLICATION HISTORY Acta Physiologica 2006– Acta Physiologica Scandinavica 1940–2005 Skandinavisches Archiv für Physiologie 1889–1939 AAPHA_v227_s718_issueinfo.inddPHA_v227_s718_issueinfo.indd 1 88/28/2019/28/2019 9:07:319:07:31 AAMM Chief Editor INFORMATION FOR SUBSCRIBERS Pontus B. Persson, Berlin Acta Physiologica is published in 12 issues per year. Subscription prices for 2019 € Editors are: Institutional: 1059 (Europe), $1582 (The Americas), $1849 (Rest of World). Cardiovascular Physiology – Frantisek Kolar, Prague; Holger Nilsson, Gothenburg Prices are exclusive of tax. Australian GST, Canadian GST/HST and European and William E. Louch, Oslo VAT will be applied at the appropriate rates. For more information on current tax Cell Biology – Sari Lauri, Helsinki rates, please go to www.wileyonlinelibrary.com/tax-vat. The price includes online Chronobiology and Endocrinology – Charna Dibner, Geneva access to the current and all online back fi les to January 1st 2015, where available. Exercise Physiology – Jan Henriksson, Stockholm For other pricing options, including access information
    [Show full text]
  • Visualization of Chemical Space Using Principal Component Analysis
    World Applied Sciences Journal 29 (Data Mining and Soft Computing Techniques): 53-59, 2014 ISSN 1818-4952 © IDOSI Publications, 2014 DOI: 10.5829/idosi.wasj.2014.29.dmsct.10 Visualization of Chemical Space Using Principal Component Analysis B. Firdaus Begam and J. Satheesh Kumar Department of Computer Applications, School of Computer Science and Engineering, Bharathiar University, Coimbatore, Tamilnadu, India Abstract: Principal component analysis is one of the most widely used multivariate methods to visualize chemical space in new dimension by the chemist for analysing data. In Multivariate data analysis, the relationship between two variables with more number of characteristics can be considered. PCA provides a compact view of variation in chemical data matrix which helps in creating better Quantitative Structure Activity Relationship (QSAR) model. It highlights the dominating pattern in the matrix through principal component and graphical representation. This paper focuses on mathematical aspects of principal components and role of PCA on Maybridge dataset to identify dominating hidden patterns of drug likeness based on Lipinski RO5. Key words: Principal Component Analysis Load p lot Score plot Biplot INTRODUCTION a new model of selected objects and variables with minimal loss of information. It can also be used for Principal Component Analysis (PCA) is a multivariate prediction model as PCA acts as exploratory tool for data statistical approach to analyze data in lower dimensional analysis by calculating the variance among the variables space. PCA used vector space transformation technique which are uncorrelated [8]. to view datasets from higher-dimensional space to lower Chemical space (drug space) is defined as dimensional space. PCA is an application of linear algebra number of descriptors calculated for each molecule [2] which was first coined by Karl Pearson during 1901 [1].
    [Show full text]
  • Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer George C
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Scholarship, Research, and Creative Work at Bryn Mawr College | Bryn Mawr College... Bryn Mawr College Scholarship, Research, and Creative Work at Bryn Mawr College Chemistry Faculty Research and Scholarship Chemistry 2018 Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer George C. Prendergast William Paul Malachowski Bryn Mawr College, [email protected] Arpita Mondal Peggy Scherle Alexander J. Muller Let us know how access to this document benefits ouy . Follow this and additional works at: https://repository.brynmawr.edu/chem_pubs Part of the Chemistry Commons Custom Citation George C. Prendergast, William J. Malachowski, Arpita Mondal, Peggy Scherle, and Alexander J. Muller. 2018. "Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer." International Review of Cell and Molecular Biology 336: 175-203. This paper is posted at Scholarship, Research, and Creative Work at Bryn Mawr College. https://repository.brynmawr.edu/chem_pubs/25 For more information, please contact [email protected]. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer George C. Prendergast, William, Malachowski, Arpita Mondal, Peggy Scherle, and Alexander J. Muller International Review of Cell and Molecular Biology 336: 175-203. http://doi.org/10.1016/bs.ircmb.2017.07.004 ABSTRACT The tryptophan catabolic enzyme indoleamine 2,3-dioxygenase-1 (IDO1) has attracted enormous attention in driving cancer immunosuppression, neovascularization, and metastasis. IDO1 suppresses local CD8+ T effector cells and natural killer cells and induces CD4+ T regulatory cells (iTreg) and myeloid-derived suppressor cells (MDSC). The structurally distinct enzyme tryptophan dioxygenase (TDO) also has been implicated recently in immune escape and metastatic progression.
    [Show full text]
  • Generated by SRI International Pathway Tools Version 25.0, Authors S
    Authors: Pallavi Subhraveti Peter D Karp Ingrid Keseler An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Anamika Kothari Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_000223375Cyc: Ketogulonicigenium vulgare WSH-001 (GCF_000223375) Cellular Overview Connections between pathways are omitted for legibility. Ron Caspi a sulfonate a sulfonate L-arabinose L-arabinose L-arabinose L-arabinose L-arabinose spermidine nitrate nitrate phosphate D-galactose D-galactose D-galactose D-galactose D-galactose 3+ 3+ putrescine L-ornithine L-ornithine L-ornithine L-ornithine a sulfonate a sulfonate a sulfonate a sulfonate a sulfonate hydrogencarbonate hydrogencarbonate a sulfonate Fe Fe an amino glycine betaine D-allose D-allose D-allose D-allose D-allose spermidine spermidine spermidine sn-glycerol sn-glycerol spermidine lys lys lys lys molybdate molybdate molybdate molybdate nitrate nitrate nitrate nitrate nitrate nitrate thiosulfate thiosulfate thiosulfate thiosulfate thiosulfate thiosulfate spermidine spermidine ammonium a glycerophosphodiester acid L-carnitine phosphate phosphate phosphate benzoate hydrogencarbonate hydrogencarbonate hydrogencarbonate hydrogencarbonate hydrogencarbonate hydrogencarbonate
    [Show full text]